Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations
SUMMARY The effect on steatorrhoea of a pH‐sensitive enteric‐coated pancreatic preparation (Eurobiol 25 000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enz...
Gespeichert in:
Veröffentlicht in: | Alimentary pharmacology & therapeutics 1991-08, Vol.5 (4), p.365-378 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 378 |
---|---|
container_issue | 4 |
container_start_page | 365 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 5 |
creator | DELCHIER, J.‐C. VIDON, N. GIRARDIN, M.‐F. SAINT‐MARC SOULE, J.‐C. MOULIN, C. HUCHET, B. ZYLBERBERG, P. |
description | SUMMARY
The effect on steatorrhoea of a pH‐sensitive enteric‐coated pancreatic preparation (Eurobiol 25 000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enzymes in the upper digestive tract was evaluated by measuring gastric and duodenal pH, amount of enzymes in the stomach, duodenal enzyme output, and fat absorption at the angle of Treitz for the 4 hours following a standard meal. When compared with placebo, Eurobiol and Eurobiol 25 000 reduced daily faecal fat excretion by 24% (not significant) and 43% (P < 0.05), respectively. With the conventional preparation, enzyme output and fat absorption at the duodeno‐jejunal flexure were significantly improved (P < 0.05). Marked inter‐individual differences in duodenal enzyme recovery (lipase 3% to 80%; chymotrypsin 26% to 100%) and, consequently, in the reduction of steatorrhoea (0% to 67%) were observed, with the gastric emptying rate emerging as a key determinant factor. With the enteric‐coated preparation, enzyme output and fat absorption at the duodenojejunal flexure were not significantly improved. Discrepancy between the marked reduction of faecal fat excretion and the low duodenal enzyme recovery could indicate that enzyme delivery from microtablets occurs further down in the small bowel. Efficacy of enteric‐coated preparations could be enhanced by adding unprotected enzymes, especially in patients with rapid gastric emptying. |
doi_str_mv | 10.1111/j.1365-2036.1991.tb00040.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72623244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72623244</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3145-3d43f7ac1c51d767959b7831fcacc1cea869133595ff049d326299d1668ca5033</originalsourceid><addsrcrecordid>eNqVkF1LxSAYxyWKOr18hGAEdbelc-rsIjhEbxDURV2Lx2l42ObSHTrr0-fYqG7zRnz-v-dRfwCcIZihuC7XGcKUpDnENEOco6xfQQgLmG13wOIn2gULmFOe5iXCB-AwhHWEKIP5PthHjDFSsAVo7mSvE2cS52VdD4lt33XodZXo9mtodIiFpJOt8lr2VsVT2BhjldWtGq4S5ZpOehtcO47oP91fdpqQdF5HJlZcG47BnpF10CfzfgTe7m5fbx7Sp-f7x5vlU6owKkiKqwIbJhVSBFWMMk74ipUYGSVVLGpZUo4wJpwYAwte4ZzmnFeI0lJJAjE-AhfT3M67j038kGhsULquZavdJggWG3BeFBG8mkDlXQheG9F520g_CATF6FqsxShUjELF6FrMrsU2Np_Ot2xWja5-Wye5MT-fcxmUrI2Pbmz4xXhJMMEjdz1xn7bWwz9eIJYvrzHC3xaInSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72623244</pqid></control><display><type>article</type><title>Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>DELCHIER, J.‐C. ; VIDON, N. ; GIRARDIN, M.‐F. SAINT‐MARC ; SOULE, J.‐C. ; MOULIN, C. ; HUCHET, B. ; ZYLBERBERG, P.</creator><creatorcontrib>DELCHIER, J.‐C. ; VIDON, N. ; GIRARDIN, M.‐F. SAINT‐MARC ; SOULE, J.‐C. ; MOULIN, C. ; HUCHET, B. ; ZYLBERBERG, P.</creatorcontrib><description>SUMMARY
The effect on steatorrhoea of a pH‐sensitive enteric‐coated pancreatic preparation (Eurobiol 25 000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enzymes in the upper digestive tract was evaluated by measuring gastric and duodenal pH, amount of enzymes in the stomach, duodenal enzyme output, and fat absorption at the angle of Treitz for the 4 hours following a standard meal. When compared with placebo, Eurobiol and Eurobiol 25 000 reduced daily faecal fat excretion by 24% (not significant) and 43% (P < 0.05), respectively. With the conventional preparation, enzyme output and fat absorption at the duodeno‐jejunal flexure were significantly improved (P < 0.05). Marked inter‐individual differences in duodenal enzyme recovery (lipase 3% to 80%; chymotrypsin 26% to 100%) and, consequently, in the reduction of steatorrhoea (0% to 67%) were observed, with the gastric emptying rate emerging as a key determinant factor. With the enteric‐coated preparation, enzyme output and fat absorption at the duodenojejunal flexure were not significantly improved. Discrepancy between the marked reduction of faecal fat excretion and the low duodenal enzyme recovery could indicate that enzyme delivery from microtablets occurs further down in the small bowel. Efficacy of enteric‐coated preparations could be enhanced by adding unprotected enzymes, especially in patients with rapid gastric emptying.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.1991.tb00040.x</identifier><identifier>PMID: 1777547</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Bile Acids and Salts - metabolism ; Biological and medical sciences ; Celiac Disease - drug therapy ; Celiac Disease - etiology ; Celiac Disease - metabolism ; Chymotrypsin - administration & dosage ; Chymotrypsin - pharmacokinetics ; Digestive system ; Exocrine Pancreatic Insufficiency - complications ; Exocrine Pancreatic Insufficiency - drug therapy ; Exocrine Pancreatic Insufficiency - metabolism ; Feces - chemistry ; Female ; Gastric Emptying - drug effects ; Humans ; Lipase - administration & dosage ; Lipase - pharmacokinetics ; Male ; Medical sciences ; Middle Aged ; Pancreatic Extracts - administration & dosage ; Pancreatic Extracts - pharmacokinetics ; Pancreatic Extracts - therapeutic use ; Pharmacology. Drug treatments ; Tablets, Enteric-Coated</subject><ispartof>Alimentary pharmacology & therapeutics, 1991-08, Vol.5 (4), p.365-378</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3145-3d43f7ac1c51d767959b7831fcacc1cea869133595ff049d326299d1668ca5033</citedby><cites>FETCH-LOGICAL-c3145-3d43f7ac1c51d767959b7831fcacc1cea869133595ff049d326299d1668ca5033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.1991.tb00040.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.1991.tb00040.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19853537$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1777547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DELCHIER, J.‐C.</creatorcontrib><creatorcontrib>VIDON, N.</creatorcontrib><creatorcontrib>GIRARDIN, M.‐F. SAINT‐MARC</creatorcontrib><creatorcontrib>SOULE, J.‐C.</creatorcontrib><creatorcontrib>MOULIN, C.</creatorcontrib><creatorcontrib>HUCHET, B.</creatorcontrib><creatorcontrib>ZYLBERBERG, P.</creatorcontrib><title>Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>SUMMARY
The effect on steatorrhoea of a pH‐sensitive enteric‐coated pancreatic preparation (Eurobiol 25 000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enzymes in the upper digestive tract was evaluated by measuring gastric and duodenal pH, amount of enzymes in the stomach, duodenal enzyme output, and fat absorption at the angle of Treitz for the 4 hours following a standard meal. When compared with placebo, Eurobiol and Eurobiol 25 000 reduced daily faecal fat excretion by 24% (not significant) and 43% (P < 0.05), respectively. With the conventional preparation, enzyme output and fat absorption at the duodeno‐jejunal flexure were significantly improved (P < 0.05). Marked inter‐individual differences in duodenal enzyme recovery (lipase 3% to 80%; chymotrypsin 26% to 100%) and, consequently, in the reduction of steatorrhoea (0% to 67%) were observed, with the gastric emptying rate emerging as a key determinant factor. With the enteric‐coated preparation, enzyme output and fat absorption at the duodenojejunal flexure were not significantly improved. Discrepancy between the marked reduction of faecal fat excretion and the low duodenal enzyme recovery could indicate that enzyme delivery from microtablets occurs further down in the small bowel. Efficacy of enteric‐coated preparations could be enhanced by adding unprotected enzymes, especially in patients with rapid gastric emptying.</description><subject>Adult</subject><subject>Bile Acids and Salts - metabolism</subject><subject>Biological and medical sciences</subject><subject>Celiac Disease - drug therapy</subject><subject>Celiac Disease - etiology</subject><subject>Celiac Disease - metabolism</subject><subject>Chymotrypsin - administration & dosage</subject><subject>Chymotrypsin - pharmacokinetics</subject><subject>Digestive system</subject><subject>Exocrine Pancreatic Insufficiency - complications</subject><subject>Exocrine Pancreatic Insufficiency - drug therapy</subject><subject>Exocrine Pancreatic Insufficiency - metabolism</subject><subject>Feces - chemistry</subject><subject>Female</subject><subject>Gastric Emptying - drug effects</subject><subject>Humans</subject><subject>Lipase - administration & dosage</subject><subject>Lipase - pharmacokinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pancreatic Extracts - administration & dosage</subject><subject>Pancreatic Extracts - pharmacokinetics</subject><subject>Pancreatic Extracts - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Tablets, Enteric-Coated</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1LxSAYxyWKOr18hGAEdbelc-rsIjhEbxDURV2Lx2l42ObSHTrr0-fYqG7zRnz-v-dRfwCcIZihuC7XGcKUpDnENEOco6xfQQgLmG13wOIn2gULmFOe5iXCB-AwhHWEKIP5PthHjDFSsAVo7mSvE2cS52VdD4lt33XodZXo9mtodIiFpJOt8lr2VsVT2BhjldWtGq4S5ZpOehtcO47oP91fdpqQdF5HJlZcG47BnpF10CfzfgTe7m5fbx7Sp-f7x5vlU6owKkiKqwIbJhVSBFWMMk74ipUYGSVVLGpZUo4wJpwYAwte4ZzmnFeI0lJJAjE-AhfT3M67j038kGhsULquZavdJggWG3BeFBG8mkDlXQheG9F520g_CATF6FqsxShUjELF6FrMrsU2Np_Ot2xWja5-Wye5MT-fcxmUrI2Pbmz4xXhJMMEjdz1xn7bWwz9eIJYvrzHC3xaInSw</recordid><startdate>199108</startdate><enddate>199108</enddate><creator>DELCHIER, J.‐C.</creator><creator>VIDON, N.</creator><creator>GIRARDIN, M.‐F. SAINT‐MARC</creator><creator>SOULE, J.‐C.</creator><creator>MOULIN, C.</creator><creator>HUCHET, B.</creator><creator>ZYLBERBERG, P.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199108</creationdate><title>Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations</title><author>DELCHIER, J.‐C. ; VIDON, N. ; GIRARDIN, M.‐F. SAINT‐MARC ; SOULE, J.‐C. ; MOULIN, C. ; HUCHET, B. ; ZYLBERBERG, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3145-3d43f7ac1c51d767959b7831fcacc1cea869133595ff049d326299d1668ca5033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Bile Acids and Salts - metabolism</topic><topic>Biological and medical sciences</topic><topic>Celiac Disease - drug therapy</topic><topic>Celiac Disease - etiology</topic><topic>Celiac Disease - metabolism</topic><topic>Chymotrypsin - administration & dosage</topic><topic>Chymotrypsin - pharmacokinetics</topic><topic>Digestive system</topic><topic>Exocrine Pancreatic Insufficiency - complications</topic><topic>Exocrine Pancreatic Insufficiency - drug therapy</topic><topic>Exocrine Pancreatic Insufficiency - metabolism</topic><topic>Feces - chemistry</topic><topic>Female</topic><topic>Gastric Emptying - drug effects</topic><topic>Humans</topic><topic>Lipase - administration & dosage</topic><topic>Lipase - pharmacokinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pancreatic Extracts - administration & dosage</topic><topic>Pancreatic Extracts - pharmacokinetics</topic><topic>Pancreatic Extracts - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Tablets, Enteric-Coated</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DELCHIER, J.‐C.</creatorcontrib><creatorcontrib>VIDON, N.</creatorcontrib><creatorcontrib>GIRARDIN, M.‐F. SAINT‐MARC</creatorcontrib><creatorcontrib>SOULE, J.‐C.</creatorcontrib><creatorcontrib>MOULIN, C.</creatorcontrib><creatorcontrib>HUCHET, B.</creatorcontrib><creatorcontrib>ZYLBERBERG, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DELCHIER, J.‐C.</au><au>VIDON, N.</au><au>GIRARDIN, M.‐F. SAINT‐MARC</au><au>SOULE, J.‐C.</au><au>MOULIN, C.</au><au>HUCHET, B.</au><au>ZYLBERBERG, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1991-08</date><risdate>1991</risdate><volume>5</volume><issue>4</issue><spage>365</spage><epage>378</epage><pages>365-378</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>SUMMARY
The effect on steatorrhoea of a pH‐sensitive enteric‐coated pancreatic preparation (Eurobiol 25 000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enzymes in the upper digestive tract was evaluated by measuring gastric and duodenal pH, amount of enzymes in the stomach, duodenal enzyme output, and fat absorption at the angle of Treitz for the 4 hours following a standard meal. When compared with placebo, Eurobiol and Eurobiol 25 000 reduced daily faecal fat excretion by 24% (not significant) and 43% (P < 0.05), respectively. With the conventional preparation, enzyme output and fat absorption at the duodeno‐jejunal flexure were significantly improved (P < 0.05). Marked inter‐individual differences in duodenal enzyme recovery (lipase 3% to 80%; chymotrypsin 26% to 100%) and, consequently, in the reduction of steatorrhoea (0% to 67%) were observed, with the gastric emptying rate emerging as a key determinant factor. With the enteric‐coated preparation, enzyme output and fat absorption at the duodenojejunal flexure were not significantly improved. Discrepancy between the marked reduction of faecal fat excretion and the low duodenal enzyme recovery could indicate that enzyme delivery from microtablets occurs further down in the small bowel. Efficacy of enteric‐coated preparations could be enhanced by adding unprotected enzymes, especially in patients with rapid gastric emptying.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>1777547</pmid><doi>10.1111/j.1365-2036.1991.tb00040.x</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 1991-08, Vol.5 (4), p.365-378 |
issn | 0269-2813 1365-2036 |
language | eng |
recordid | cdi_proquest_miscellaneous_72623244 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adult Bile Acids and Salts - metabolism Biological and medical sciences Celiac Disease - drug therapy Celiac Disease - etiology Celiac Disease - metabolism Chymotrypsin - administration & dosage Chymotrypsin - pharmacokinetics Digestive system Exocrine Pancreatic Insufficiency - complications Exocrine Pancreatic Insufficiency - drug therapy Exocrine Pancreatic Insufficiency - metabolism Feces - chemistry Female Gastric Emptying - drug effects Humans Lipase - administration & dosage Lipase - pharmacokinetics Male Medical sciences Middle Aged Pancreatic Extracts - administration & dosage Pancreatic Extracts - pharmacokinetics Pancreatic Extracts - therapeutic use Pharmacology. Drug treatments Tablets, Enteric-Coated |
title | Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T12%3A39%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fate%20of%20orally%20ingested%20enzymes%20in%20pancreatic%20insufficiency:%20comparison%20of%20two%20pancreatic%20enzyme%20preparations&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=DELCHIER,%20J.%E2%80%90C.&rft.date=1991-08&rft.volume=5&rft.issue=4&rft.spage=365&rft.epage=378&rft.pages=365-378&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.1991.tb00040.x&rft_dat=%3Cproquest_cross%3E72623244%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72623244&rft_id=info:pmid/1777547&rfr_iscdi=true |